Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: A randomized double-blind clinical trial

Epilepsia

Volumn 51, Issue 10, 2010, Pages 1970-1977

  Ramsay, Eugene ^a   Faught, Edward ^b   Krumholz, Allan ^c   Naritoku, Dean ^d,g   Privitera, Michael ^e   Schwarzman, Lesley ^f   Mao, Lian ^f   Wiegand, Frank ^b,h   Hulihan, Joseph ^f  

^a Ochsner Baptist Medical Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d SOUTHERN ILLINOIS UNIVERSITY   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^g UNIVERSITY OF SOUTH ALABAMA   (United States)

^h JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Complex partial seizures; Epilepsy; Generalized tonic clonic seizures; Phenytoin; Rapid initiation; Topiramate

Indexed keywords

PHENYTOIN; TOPIRAMATE;

ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; ATTENTION DISTURBANCE; CEREBROVASCULAR DISEASE; CHILD; CLINICAL TRIAL; COGNITIVE DEFECT; COMPARATIVE STUDY; COMPLEX PARTIAL SEIZURE; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GRAND MAL SEIZURE; HEART FAILURE; HEMIPARESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; SYNCOPE; TONIC CLONIC SEIZURE; TREATMENT DURATION; VISUAL DISORDER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; EMERGENCY MEDICAL SERVICES; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 78649265245     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2010.02670.x     Document Type: Article

References (36)

1. Aronson JK, Hardman M, Reynolds DJ,. (1992) ABC of monitoring drug therapy. Phenytoin. BMJ 305: 1215-1218.
2. Arroyo S, Dodson WE, Privitera MD, Glauser TA, Naritoku DK, Dlugos DJ, Wang S, Schwabe SK, Twyman RE,. (2005) Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 112: 214-222.
3. Banh HL, Burton ME, Sperling MR,. (2002) Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit 24: 379-385.
4. Berg AT,. (2008) Risk of recurrence after a first unprovoked seizure. Epilepsia 49 (Suppl 1): 13-18.
5. Bill PA, Vigonius U, Pohlmann H, Guerreiro CA, Kochen S, Saffer D, Moore A,. (1997) A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 27: 195-204. (Pubitemid 27306800)
6. Biton V, Edwards KR, Montouris GD, Sackellares JC, Harden CL, Kamin M,. (2001) Topiramate titration and tolerability. Ann Pharmacother 35: 173-179.
7. Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, De Krom M, Aldenkamp AP,. (2008) Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison. Seizure 17: 19-26.
8. Cloyd JC, Gumnit RJ, McLain LW Jr,. (1980) Status epilepticus. The role of intravenous phenytoin. JAMA 244: 1479-1481.
9. Dilantin PI,. (2009) Parke-Davis, Division of Pfizer, New York, April 2009.
10. Fisher RS, Sachdeo RC, Pellock J, Penovich PE, Magnus L, Bernstein P,. (2001) Rapid initiation of gabapentin: a randomized, controlled trial. Neurology 56: 743-748.
11. Gilliam FG, Veloso F, Bomhof MA, Gazda SK, Biton V, Ter Bruggen JP, Neto W, Bailey C, Pledger G, Wu SC,. (2003) A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 60: 196-202.
12. Glauser TA, Dlugos DJ, Dodson WE, Grinspan A, Wang S, Wu SC,. (2007) Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. J Child Neurol 22: 693-699.
13. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E,. (1999) Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 40: 985-991.
14. Hauser WA, Rich SS, Lee JR, Annegers JF, Anderson VE,. (1998) Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 338: 429-434.
15. Huff JS, Morris DL, Kothari RU, Gibbs MA,. (2001) Emergency department management of patients with seizures: a multicenter study. Acad Emerg Med 8: 622-628.
16. Koubeissi MZ, Amina S, Pita I, Bergey GK, Werz MA,. (2008) Tolerability and efficacy of oral loading of levetiracetam. Neurology 70: 2166-2170.
17. Latini G, Verrotti A, Manco R, Scardapane A, Del Vecchio A, Chiarelli F,. (2008) Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy. Mini Rev Med Chem 8: 10-23.
18. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR,. (2007a) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369: 1000-1015.
19. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR,. (2007b) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369: 1016-1026. (Pubitemid 46436125)
20. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB, Homan RW, Crill WE, Lubozynski MF, Rosenthal NP, Mayersdorf MD., (1985) Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 313: 145-151.
21. Mattson RH, Cramer JA, Collins JF,. (1992) A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 327: 765-771.
22. Ortho-McNeil (20032004). Ortho-McNeil neurology consultant surveys, 2003-2004.
23. Ortho-McNeil (2008). Topamax product information sheet. Ortho-McNeil Janssen Scientific Affairs, Philadelphia. April 2008.
24. Osborn HH, Zisfein J, Sparano R,. (1987) Single-dose oral phenytoin loading. Ann Emerg Med 16: 407-412.
25. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S,. (2003) Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 107: 165-175.
26. Purcell TB, McPheeters RA, Feil M, Chavez R,. (2007) Rapid oral loading of carbamazepine in the emergency department. Ann Emerg Med 50: 121-126.
27. Ramos Lizana J, Cassinello Garcia E, Carrasco Marina LL, Vazquez Lopez M, Martin Gonzalez M, Munoz Hoyos A,. (2000) Seizure recurrence after a first unprovoked seizure in childhood: a prospective study. Epilepsia 41: 1005-1013.
28. Schmidt D, Haenel F,. (1984) Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type. Neurology 34: 1252-1255.
29. Schmidt D, Einicke I, Haenel F,. (1986) The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine. Arch Neurol 43: 263-265.
30. So EL, Penry JK,. (1981) Adverse effects of phenytoin on peripheral nerves and neuromuscular junction: a review. Epilepsia 22: 467-473.
31. Steiner TJ, Dellaportas CI, Findley LJ, Gross M, Gibberd FB, Perkin GD, Park DM, Abbott R,. (1999) Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 40: 601-607.
32. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR,. (1990) A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 323: 497-502.
33. Trevisol-Bittencourt PC, Da Silva VR, Molinari MA, Troiano AR,. (1999) Phenytoin as the first option in female epileptic patients? Arq Neuropsiquiatr 57: 784-786.
34. Van Der Meyden CH, Kruger AJ, Muller FO, Rabie W, Schall R,. (1994) Acute oral loading of carbamazepine-CR and phenytoin in a double-blind randomized study of patients at risk of seizures. Epilepsia 35: 189-194.
35. Wilder BJ, Serrano EE, Ramsay RE,. (1973) Plasma diphenylhydantoin levels after loading and maintenance doses. Clin Pharmacol Ther 14: 797-801.
36. Wong IC, Mawer GE, Sander JW,. (1999) Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 33: 1037-1042.